- Home
- PSNL vs LENZ Comparison
PSNL vs LENZ Comparison
Compare PSNL & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | LENZ |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 609.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNL | LENZ |
|---|---|---|
| Price | $9.53 | $16.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $11.17 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.41 | $203.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $14.43 |
| 52 Week High | $11.50 | $50.40 |
Technical Indicators
Market Signals| Indicator | PSNL | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 39.58 |
| Support Level | $9.01 | $19.26 |
| Resistance Level | $10.69 | $21.80 |
| Average True Range (ATR) | 0.80 | 1.58 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 34.21 | 22.35 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.